As putative binding partners for the well-known coinhibitory molecule VISTA, both VSIG3 and VSIG8 were able to negatively regulate T-cell responses and can be targeted in certain cancer types in which antitumor immunity is predominantly affected by the VISTA pathway. The gene discussed is VSIG8; the disease is cancer.